TR201902233T4 - Fast dissolving solid dosage form. - Google Patents

Fast dissolving solid dosage form. Download PDF

Info

Publication number
TR201902233T4
TR201902233T4 TR2019/02233T TR201902233T TR201902233T4 TR 201902233 T4 TR201902233 T4 TR 201902233T4 TR 2019/02233 T TR2019/02233 T TR 2019/02233T TR 201902233 T TR201902233 T TR 201902233T TR 201902233 T4 TR201902233 T4 TR 201902233T4
Authority
TR
Turkey
Prior art keywords
dosage form
solid dosage
fast dissolving
dissolving solid
biologically active
Prior art date
Application number
TR2019/02233T
Other languages
Turkish (tr)
Inventor
Beng Stephen Lim Chin
Bruce Sunderland Vivian
Hang Eddy Lee Yip
Original Assignee
Ix Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ix Biopharma Ltd filed Critical Ix Biopharma Ltd
Publication of TR201902233T4 publication Critical patent/TR201902233T4/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Ağız boşluğunda biyolojik olarak aktif bir maddenin serbest bırakılması için uyarlanmış hızlı çözünen bir katı dozaj formu temin edilmiştir ve buradaki dozaj formu, en azından bir biyolojik açıdan aktif malzeme ve en az bir matris oluşturucu ajan ihtiva eder, burada dozaj formu ağız boşluğunda büyük ölçüde erir. Aynı maddenin imalatı için bir yöntem ve bunu içeren bir kit de ayrıca temin edilmektedir.A fast dissolving solid dosage form adapted for the release of a biologically active substance in the oral cavity is provided, wherein the dosage form comprises at least one biologically active material and at least one matrix forming agent, wherein the dosage form dissolves substantially in the oral cavity. A method of manufacturing the same article and a kit containing it are also provided.

TR2019/02233T 2009-10-30 2010-10-26 Fast dissolving solid dosage form. TR201902233T4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SG2009072216 2009-10-30

Publications (1)

Publication Number Publication Date
TR201902233T4 true TR201902233T4 (en) 2019-03-21

Family

ID=43922359

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/02233T TR201902233T4 (en) 2009-10-30 2010-10-26 Fast dissolving solid dosage form.

Country Status (18)

Country Link
US (4) US10744086B2 (en)
EP (3) EP3332772A1 (en)
JP (1) JP5777170B2 (en)
KR (1) KR101612073B1 (en)
CN (2) CN102933207B (en)
AU (1) AU2010313785C1 (en)
CA (1) CA2777218C (en)
DK (2) DK3254676T3 (en)
ES (2) ES2641821T3 (en)
HK (1) HK1251914A1 (en)
MY (1) MY150626A (en)
NO (1) NO2493457T3 (en)
NZ (1) NZ599594A (en)
PL (2) PL3254676T3 (en)
SG (1) SG174465A1 (en)
TR (1) TR201902233T4 (en)
WO (1) WO2011053251A1 (en)
ZA (1) ZA201400310B (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10172810B2 (en) * 2003-02-24 2019-01-08 Pharmaceutical Productions, Inc. Transmucosal ketamine delivery composition
US12186426B2 (en) 2009-10-30 2025-01-07 Ix Biopharma Ltd. Solid dosage form
TR201902233T4 (en) 2009-10-30 2019-03-21 Ix Biopharma Ltd Fast dissolving solid dosage form.
EP3095441B1 (en) * 2010-10-08 2020-12-02 R.P. Scherer Technologies, LLC Oral vaccine fast-dissolving dosage form using starch
US8722636B2 (en) 2011-01-31 2014-05-13 New Market Pharmaceuticals, LLC Animal treatments
BR112014027352B1 (en) 2012-05-02 2022-10-25 New Market Pharmaceuticals PHARMACEUTICAL COMPOSITIONS FOR DIRECT SYSTEMIC INTRODUCTION
CN102784117A (en) * 2012-08-23 2012-11-21 海南卫康制药(潜山)有限公司 Gentamicin sulfate composition freeze-dried orally disintegrating tablet and preparation method thereof
CA2886573C (en) * 2012-10-11 2019-04-02 Stephen Lim Chin Beng Solid dosage form
KR102007798B1 (en) * 2013-05-30 2019-08-07 (주)아모레퍼시픽 Cosmetic kit containing bubbling tablet and skin water
TR201905586T4 (en) * 2013-07-22 2019-05-21 Sandoz Ag FORMULATIONS CONTAINING AMORF DAPAGLIFLOZINE
US9456981B2 (en) * 2014-02-13 2016-10-04 Cadila Healthcare Limited Stable orally disintegrating tablets of hyoscyamine
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
KR20170003414A (en) * 2015-06-30 2017-01-09 (주)아모레퍼시픽 Fast soluble type granule pill composition for hair washing
CN108024952A (en) * 2015-07-16 2018-05-11 斯威普有限公司 It is used to buccal in treatment breaks out apply to obtain the midazolam compositions of quick acting
US20210322537A1 (en) * 2016-06-07 2021-10-21 Aridis Pharmaceuticals, Inc. Method For Preparation of Quick Dissolving Thin Films Containing Bioactive Material With Enhanced Thermal Stability
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
WO2018091473A1 (en) 2016-11-15 2018-05-24 Klaria Pharma Holding Ab Pharmaceutical formulation
GB201709141D0 (en) 2017-06-08 2017-07-26 Klaria Pharma Holding Ab Pharmaceutical formulation
CN109381448A (en) * 2017-08-04 2019-02-26 广州朗圣药业有限公司 A kind of razaxaban oral quick-dissolving film preparation and preparation method thereof
PL3505157T3 (en) 2017-12-29 2022-04-11 Celon Pharma S.A. Dry powder ketamine composition for pulmonary administration in treatment-resistant depression
WO2019186357A1 (en) * 2018-03-26 2019-10-03 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
WO2019215862A1 (en) * 2018-05-10 2019-11-14 救急薬品工業株式会社 Evaluation method for cytochrome p450 metabolic activity
GB201808462D0 (en) 2018-05-23 2018-07-11 Klaria Pharma Holding Ab Pharmaceutical formulation
WO2019246074A1 (en) * 2018-06-18 2019-12-26 Synergistic Therapeutics, Llc Sublingual antidepressant and antianxiety tablet
BR112021004053A2 (en) 2018-09-07 2021-05-25 Aquestive Therapeutics, Inc. oral film compositions and dosage forms having accurate active dissolution profiles
AU2020330527A1 (en) * 2019-08-12 2022-02-24 Tenshi Kaizen Private Limited Cannabidiol orally disintegrating tablets
US20210308075A1 (en) * 2020-04-07 2021-10-07 Joseph Habboushe Prevention and treatment of virial infections
CN113633616B (en) * 2020-05-11 2024-08-23 鲁南制药集团股份有限公司 A solid preparation with high bioavailability
WO2021241898A1 (en) * 2020-05-26 2021-12-02 주식회사 경보제약 Veterinary orally-disintegrating-film formulation for treating or preventing parasitic infectious diseases in animals
US20240350434A1 (en) * 2020-06-02 2024-10-24 Ix Biopharma Limited Methods for treating major depressive disorder and treatment-resistant depression
EP4157244A4 (en) * 2020-06-02 2024-07-17 IX Biopharma Limited METHODS FOR TREATING SEVERE AND TREATMENT-RESISTANT DEPRESSION
BR112023001716A2 (en) * 2020-07-31 2023-04-04 Catalent Uk Swindon Zydis Ltd PHARMACEUTICAL COMPOSITIONS COMPRISING COATED API
KR20230069951A (en) * 2020-09-08 2023-05-19 쏜 헬스테크, 인크. soluble matrix
US20230364013A1 (en) * 2020-10-08 2023-11-16 Catalent U.K. Swindon Zydis Limited Stable oral dispersible formulation for epinephrine
CN113693999A (en) * 2020-12-10 2021-11-26 洛里·安妮·玛丽·米亚斯 Solid composition for dissolving in fluid cosmetic and fluid cosmetic
CN113244183A (en) * 2021-06-07 2021-08-13 河南合智医药科技有限公司 Inosine oral instant tablet and preparation method thereof
JP2024533724A (en) * 2021-09-24 2024-09-12 ドナルドソン，チャドウィック Dry powder effervescent formulation for drug delivery across mucous membranes - Patents.com
WO2024180208A1 (en) 2023-03-01 2024-09-06 Swipp Ab Oral film unit dosage form
WO2025171445A1 (en) * 2024-02-14 2025-08-21 Ix Biopharma Limited Compositions and methods for delivering nad

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2036890B1 (en) * 1969-04-15 1973-01-12 Orsymonde
JPS4868726A (en) * 1971-12-27 1973-09-19
US4946684A (en) * 1989-06-20 1990-08-07 American Home Products Corporation Fast dissolving dosage forms
US5215756A (en) 1989-12-22 1993-06-01 Gole Dilip J Preparation of pharmaceutical and other matrix systems by solid-state dissolution
US5558880A (en) * 1989-12-22 1996-09-24 Janssen Pharmaceutica Inc. Pharmaceutical and other dosage forms
DE4020144A1 (en) 1990-06-25 1992-01-09 Lohmann Therapie Syst Lts Patches for topical or transdermal drug delivery - with adhesive layer contg. polyacrylate adhesive and film former
US5298261A (en) 1992-04-20 1994-03-29 Oregon Freeze Dry, Inc. Rapidly distintegrating tablet
IL105553A (en) * 1992-05-06 1998-01-04 Janssen Pharmaceutica Inc Solid dosage form comprising a porous network of matrix forming material which disperses rapidly in water
FI962989A0 (en) * 1994-01-27 1996-07-26 Univ Oklahoma Quickly soluble oral dosage form
US5698217A (en) 1995-05-31 1997-12-16 Minnesota Mining And Manufacturing Company Transdermal drug delivery device containing a desiccant
GB9517062D0 (en) 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
GB9700878D0 (en) 1997-01-17 1997-03-05 Scherer Ltd R P Dosage forms and method for ameliorating male erectile dysfunction
WO1998036738A1 (en) 1997-02-20 1998-08-27 Therics, Inc. Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same
US6024981A (en) * 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
US5976577A (en) 1997-07-11 1999-11-02 Rp Scherer Corporation Process for preparing fast dispersing solid oral dosage form
GB9717770D0 (en) 1997-08-21 1997-10-29 Scherer Ltd R P Pharmaceutical composition
GB9802088D0 (en) 1998-01-30 1998-03-25 Scherer Ltd R P Pharmaceutical products
US6465009B1 (en) * 1998-03-18 2002-10-15 Yamanouchi Pharmaceutical Co., Ltd. Water soluble polymer-based rapidly dissolving tablets and production processes thereof
US6200604B1 (en) 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
US6974590B2 (en) 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
ES2257869T3 (en) 1998-08-21 2006-08-01 Novartis Ag NEW ORAL FORMULATION FOR AGONISTS OR ANTAGONISTS OF 5-HT4.
SE9803240D0 (en) 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
SE9803239D0 (en) 1998-09-24 1998-09-24 Diabact Ab Composition for the treatment of acute pain
US6596298B2 (en) 1998-09-25 2003-07-22 Warner-Lambert Company Fast dissolving orally comsumable films
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
GB9901819D0 (en) 1999-01-27 1999-03-17 Scherer Corp R P Pharmaceutical compositions
GB9904911D0 (en) 1999-03-03 1999-04-28 Scherer Ltd R P Pharmaceutical compositions
AU2004242477B2 (en) 1999-03-26 2007-04-19 Cima Labs Inc. Sublingual buccal effervescent
AU2007203233B2 (en) 1999-03-26 2010-02-25 Cima Labs Inc. Sublingual buccal effervescent
GB9908014D0 (en) 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
EP1202716A1 (en) * 1999-08-17 2002-05-08 Novartis Consumer Health S.A. Rapidly dissolving dosage form and process for making same
EP1231900A1 (en) * 1999-11-23 2002-08-21 The Robert Gordon University Bilayered buccal tablets comprising nicotine
DE19959913A1 (en) 1999-12-11 2001-06-28 Lohmann Therapie Syst Lts Transdermal system for the treatment of migraines containing acetylsalicylic acid
JP2001278812A (en) 2000-03-27 2001-10-10 Kyoto Pharmaceutical Industries Ltd Disintegrant for tablet and tablet using the same
AU2001266956A1 (en) 2000-06-16 2002-01-02 Evaltec Personnel golfing assistant
US7118498B2 (en) 2000-06-16 2006-10-10 Skyhawke Technologies, Llc Personal golfing assistant and method and system for graphically displaying golf related information and for collection, processing and distribution of golf related data
EP1301186A1 (en) * 2000-07-19 2003-04-16 Lavipharm Laboratories, Inc. Sildenafil citrate solid dispersions having high water solubility
US7510728B2 (en) 2000-10-06 2009-03-31 Takeda Pharmaceutical Company Limited Solid preparations
JP4284017B2 (en) 2000-10-06 2009-06-24 武田薬品工業株式会社 Solid preparation
US6509040B1 (en) * 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US20080050422A1 (en) * 2001-10-12 2008-02-28 Monosolrx, Llc. Method of administering a film product containing a drug
EP1458367B2 (en) 2001-10-12 2021-01-27 Aquestive Therapeutics, Inc. Uniform films for rapidly dissolving dosage form incorporating taste-masking compositions
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
ATE536869T1 (en) 2001-10-12 2011-12-15 Monosolrx Llc GLUCAN FILM BASED DRUG DELIVERY SYSTEMS
CA2473967C (en) 2001-10-12 2011-06-14 Monosolrx Llc Thin film with non-self-aggregating uniform heterogeneity, process for their production and drug delivery systems made therefrom
US7425292B2 (en) 2001-10-12 2008-09-16 Monosol Rx, Llc Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US7118765B2 (en) * 2001-12-17 2006-10-10 Spi Pharma, Inc. Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
US20030224090A1 (en) * 2002-02-11 2003-12-04 Edizone, Lc Snacks of orally soluble edible films
US20040247649A1 (en) * 2002-02-11 2004-12-09 Edizone, Lc Medicine-containing orally soluble films
DE10207394B4 (en) 2002-02-21 2007-03-29 Lts Lohmann Therapie-Systeme Ag Taste-masked oblate medicinal preparation
GB0210397D0 (en) * 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
GB0226076D0 (en) 2002-11-08 2002-12-18 Rp Scherer Technologies Inc Improved formulations containing substituted imidazole derivatives
JP4776233B2 (en) * 2002-11-12 2011-09-21 エラン ファーマ インターナショナル，リミティド Fast disintegrating solid formulation that is resistant to abrasion and contains pullulan
WO2004066986A1 (en) 2003-01-30 2004-08-12 Monosolrx Llc Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
CA2512559A1 (en) 2003-01-31 2004-08-12 Orexo Ab A rapid-acting pharmaceutical composition
AU2004216559B2 (en) * 2003-02-28 2010-05-27 Alk-Abello A/S Dosage form having a saccharide matrix
AU2004319243B2 (en) 2003-05-28 2010-06-03 Aquestive Therapeutics, Inc. Polyethylene oxide-based films and drug delivery systems made therefrom
AU2004284080B2 (en) * 2003-10-24 2008-10-02 Adhesives Research, Inc. Disintegratable films for diagnostic devices
EP1713450B1 (en) * 2004-01-30 2021-10-06 Corium, Inc. Rapidly dissolving film for delivery of an active agent
TWI342222B (en) 2004-03-08 2011-05-21 Medical & Pharm Ind Tech & Dev Pharmaceutical composition of rapidly dissolving tablet and method of fabricating the same
EP1591107A1 (en) * 2004-04-28 2005-11-02 Pfizer GmbH Arzneimittelwerk Gödecke Process for the selective increase of a release rate of an active material from a pharmaceutical composition
EP1621186A1 (en) * 2004-07-29 2006-02-01 Cephalon France Modafinil oral lyophilizate
CA2581851C (en) 2004-09-30 2016-11-01 Monosolrx Llc Multi-layer films having uniform content
MX2007009635A (en) 2005-02-10 2007-09-25 Orexo Ab Pharmaceutical compositions useful in the transmucosal administration of drugs.
US20060207911A1 (en) * 2005-03-15 2006-09-21 Bullock John D Emergency medical treatment system
EP1863456A1 (en) 2005-03-28 2007-12-12 Orexo AB New pharmaceutical compositions useful in the treatment of pain
DE102005015128B4 (en) 2005-03-31 2008-12-11 Bayer Schering Pharma Aktiengesellschaft Wafers containing steroid hormones
CN101166531A (en) 2005-04-20 2008-04-23 日绊株式会社 percutaneous absorption preparation
US20070031349A1 (en) 2005-06-23 2007-02-08 David Monteith Rapidly absorbing oral formulations of PDE 5 inhibitors
KR20130016386A (en) * 2005-08-10 2013-02-14 시오노기세이야쿠가부시키가이샤 Orally disintegratable tablet
CA2621263A1 (en) 2005-09-09 2007-03-15 Garry L. Myers Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
WO2007028247A1 (en) 2005-09-09 2007-03-15 University Of Manitoba Fast-disintegrating epinephrine tablets for buccal or sublingual administration
JP5507840B2 (en) * 2005-09-19 2014-05-28 ユニバーシティ・オブ・ザ・ウィットウォータースランド・ヨハネスブルグ Oral mucosa pharmaceutical dosage form
US20070092553A1 (en) 2005-10-21 2007-04-26 Pfab Lp Compositions and methods of making rapidly dissolving lonically masked formulations
TWI389709B (en) 2005-12-01 2013-03-21 Novartis Ag Transdermal therapeutic system
AU2006322050A1 (en) 2005-12-06 2007-06-14 Monosol Rx, Llc Topical film compositions for delivery of actives
JP2009521532A (en) 2005-12-27 2009-06-04 モノソル アールエックス リミテッド ライアビリティ カンパニー PH-adjusted film for releasing active substances
GB0607085D0 (en) 2006-04-07 2006-05-17 Smithkline Beecham Corp Novel compositions
TW200817049A (en) 2006-06-05 2008-04-16 Verus Pharmaceuticals Inc Epinephrine dosing regimens comprising buccal, lingual or sublingual and injectable dosage forms
TWI343262B (en) * 2006-09-26 2011-06-11 Schering Corp Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
US8470361B2 (en) 2006-12-04 2013-06-25 Orexo Ab Non-abusable pharmaceutical composition comprising opioids
US20080220029A1 (en) * 2007-03-05 2008-09-11 Charlene Ng Fast-dissolving/disintegrating film preparation having high proportion of active
CN101084891A (en) 2007-06-29 2007-12-12 北京本草天源药物研究院 Darifenacin or its pharmaceutical salt pharmaceutical preparation for oral
US20090047350A1 (en) 2007-08-17 2009-02-19 Ramesh Bangalore Perforated water soluble polymer based edible films
WO2009045022A2 (en) 2007-10-03 2009-04-09 C.L. Pharm Edible film
KR100905027B1 (en) 2007-10-03 2009-06-30 (주)씨엘팜 Edible Film
DE102008014533A1 (en) 2008-03-15 2009-09-17 Lts Lohmann Therapie-Systeme Ag Gingival wafer
CN101332197B (en) * 2008-03-25 2010-12-08 江苏奥赛康药业有限公司 Loperamide hydrochloride dimethicone compound oral instant film
US8623401B2 (en) * 2008-03-27 2014-01-07 Fenwafe Inc. Wafer formulation
JP5577241B2 (en) * 2008-03-31 2014-08-20 旭化成ケミカルズ株式会社 Processed starch powder with excellent disintegration and process for producing the same
JP5122380B2 (en) * 2008-06-16 2013-01-16 エーザイ・アール・アンド・ディー・マネ�����ン��株式会社 Quick-disintegrating tablet with controlled drug release and process for producing the same
AU2009269958A1 (en) 2008-07-11 2010-01-14 Ix Biopharma Pte Ltd Opioid agonist compositions for pain management
US8715715B2 (en) 2008-11-03 2014-05-06 Nal Pharmaceuticals Ltd. Dosage form for insertion into the mouth
PL2403482T3 (en) 2009-03-04 2018-06-29 Emplicure Ab Abuse resistant formulation
PL2427177T3 (en) 2009-05-08 2018-09-28 Emplicure Ab Composition for sustained drug delivery comprising geopolymeric binder
TR201902233T4 (en) 2009-10-30 2019-03-21 Ix Biopharma Ltd Fast dissolving solid dosage form.
US12186426B2 (en) 2009-10-30 2025-01-07 Ix Biopharma Ltd. Solid dosage form
EP2515886B1 (en) 2009-12-22 2018-04-11 Luye Pharma AG Transdermal therapeutic system for administering rivastigmine or derivatives thereof
KR20130012067A (en) 2010-03-23 2013-01-31 비오알리앙스 파르마 Fast dissolving drug delivery systems
JO3112B1 (en) 2010-03-29 2017-09-20 Ferring Bv A fast dissolving pharmaceutical composition
BR112013001550A2 (en) 2010-07-21 2016-05-24 3M Innovative Properties Co compositions, devices and methods of transdermal adhesives
JP2012051875A (en) 2010-08-03 2012-03-15 Hisamitsu Pharmaceut Co Inc Method for storing transdermally/transmucosally absorbable preparation, and package of transdermally/transmucosally absorbable preparation
FR2967066B1 (en) 2010-11-04 2013-06-14 Ethypharm Sa SUBLINGUAL USE OF NON-COMPRESSED MICROGRANULES
BR112014005134A2 (en) 2011-09-16 2017-04-18 Ferring Bv fast dissolving pharmaceutical composition
JP5841433B2 (en) 2012-01-11 2016-01-13 日東電工株式会社 Intraoral film-form base and preparation
SG11201404815YA (en) 2012-02-28 2014-10-30 Nichiban Kk Transdermal patch
KR20140038237A (en) 2012-09-20 2014-03-28 에스케이케미칼주식회사 Medical product showing improved stability of rivastigmine
GB2516561B (en) 2013-03-15 2016-03-09 Aerpio Therapeutics Inc Compositions, formulations and methods for treating ocular diseases

Also Published As

Publication number Publication date
CA2777218A1 (en) 2011-05-05
DK2493457T3 (en) 2017-10-02
EP3254676B1 (en) 2018-11-28
DK3254676T3 (en) 2019-03-11
ZA201400310B (en) 2015-12-23
US20230086496A1 (en) 2023-03-23
HK1251914A1 (en) 2019-05-03
MY150626A (en) 2014-02-07
NO2493457T3 (en) 2018-01-06
CA2777218C (en) 2016-09-27
US11975097B2 (en) 2024-05-07
EP3254676A1 (en) 2017-12-13
KR101612073B1 (en) 2016-04-14
ES2641821T3 (en) 2017-11-14
US20200046637A1 (en) 2020-02-13
EP2493457A4 (en) 2013-07-03
EP3332772A1 (en) 2018-06-13
PL2493457T3 (en) 2018-01-31
NZ599594A (en) 2014-06-27
CN107811980B (en) 2021-06-18
EP2493457B1 (en) 2017-08-09
US20140178473A1 (en) 2014-06-26
AU2010313785B2 (en) 2012-11-08
CN107811980A (en) 2018-03-20
EP2493457A1 (en) 2012-09-05
US20120219628A1 (en) 2012-08-30
JP5777170B2 (en) 2015-09-09
SG174465A1 (en) 2011-10-28
US10857097B2 (en) 2020-12-08
CN102933207A (en) 2013-02-13
ES2712989T3 (en) 2019-05-17
AU2010313785C1 (en) 2019-04-11
KR20120102585A (en) 2012-09-18
US10744086B2 (en) 2020-08-18
AU2010313785A1 (en) 2011-09-08
PL3254676T3 (en) 2019-06-28
JP2013509403A (en) 2013-03-14
WO2011053251A1 (en) 2011-05-05
CN102933207B (en) 2018-02-02

Similar Documents

Publication Publication Date Title
MY150626A (en) Fast dissolving solid dosage form
HK1208353A1 (en) Solid dosage form
CY1123162T1 (en) CONTROLLED-RELEASE NITAZOXANIDE PHARMACEUTICAL FORMULATIONS
DOP2010000318A (en) IMPROVED FORMULATIONS FOR ACTIVE PHARMACEUTICAL INGREDIENTS OF DEFICIENT PERMEABILITY
CL2013000423A1 (en) Pharmaceutical dosage form with breaking strength of at least 500 n, which contains an active ingredient, an anionic polysaccharide and a polyalkylene oxide, wherein the active ingredient is present in a controlled release matrix comprising the anionic polysaccharide and the oxide of polyalkylene.
CR20110110A (en) PHARMACEUTICAL COMPOSITION
BR112012004967A2 (en) oral dosage form comprising at least one biologically active agent, formulation aids and magnetizable particles
AR087359A1 (en) TEST ALTERATION TABLET PROVIDING IMMEDIATE RELEASE OF THE PHARMACO
DE602008003522D1 (en) SOLID PREPARATION WITH ALOGLIPTIN AND PIOGLITAZONE
BRPI0908596A2 (en) prolonged release formulation and pharmaceutical composition
CL2011002968A1 (en) Hot melt extrusion dosage form of an active ingredient (a) included in a matrix comprising a polymer (c), the core having a morphological orientation orthogonal to the longitudinal direction of extension of the dosage form; and its preparation procedure.
EP2506835A4 (en) COATED AND COMPRESSIBLE PHARMACEUTICAL COMPOSITIONS, TABLETS AND METHODS OF MAKING THE SAME
MX2010005346A (en) PHARMACEUTICAL COMPOSITIONS.
BRPI0822885A2 (en) Oral Care Implement, Method for Administering an Active Agent, and Oral Care Kit
CO6390097A2 (en) FORMULATIONS FOR ORAL CARE THAT INCREASES THE AMOUNT OF ZINC SOLUBLE
CL2011001331A1 (en) Nalmefene Hydrochloride Dihydrate; methods for its preparation; pharmaceutical composition comprising it; and use for the treatment of alcoholism.
CL2009001080A1 (en) Process for encapsulating biologically active agents in a particulate carrier, comprising solubilizing in a hydrophobic ion pairing agent and a solvent, dissolving, emulsifying, and obtaining the carrier; vehicle in the form of particles; and pharmaceutical composition comprising the vehicle.
BRPI0907892A2 (en) Azatricyclic antibiotic compound, medicine, pharmaceutical composition containing and use thereof
BRPI0914336A2 (en) octreotide implantation with a release agent
CO6311067A2 (en) PREPARATION OF TABLETS WITH DELAYED RELEASE CONTAINING POLYVINROL PIRROLIDONAS AND ACTIVE PRINCIPLE
BR122020011180B8 (en) injectable formulations of tetracycline compounds
BRPI0910912A2 (en) Compound, prodrug, glucokinase activator, pharmaceutical agent, and, compound use
TR201009949T1 (en) Release modified niacin formulations.
CL2007003484A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING VALSARTAN AND A TENSOACTIVE, A LIPOFILIC COMPONENT AND A HYDROPHILIC COMPONENT; PREPARATION PROCEDURE; AND USE IN THE TREATMENT OF CARDIAC INSUFFICIENCY, ANGINA, MIOCARDIO INFARTO, ARTERIOESCLEROS
EA200702102A1 (en) PLATES CONTAINING STEROID HORMONES